Global Lipid Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Lipid Disorder Treatment Market is presumed to reach the market size of nearly USD 16.03 Billion by 2032 from USD 8.57 Billion in 2023 with a CAGR of 7.21% under the study period 2024-2032.

Lipid disorder is a metabolic condition that affects blood lipid levels. The condition causes high blood levels of low-density lipoprotein (LDL) cholesterol, and fats called triglycerides or both. High levels of LDL cholesterol and triglycerides increase the risk of developing heart disease. These levels can be reduced by some primary options such as eating less fat, exercising regularly and losing weight if one is obese. However, these options are not always effective. In such cases medication is prescribed to control the level, medications, such as statins, are effective in lowering cholesterol levels for many patients. Other medications, including bile acid sequestrants, fibric acid derivatives, cholesterol absorption inhibitors, and niacin can also help control lipid levels.

MARKET DYNAMICS

The rising global burden and growing geriatric population will be driving the growth of the market. The increasing prevalence of lipid disorders has become a global public health problem. In 2017, 4.32 million deaths were estimated owing to high low-density lipoprotein cholesterol globally. Globally geriatric population who are more prevelant to lipipd disorder is growing considerably faster than the population as a whole, and it is expected to continue growing more rapidly at least till 2050. Apart from ageing, gender, genetic susceptibility, chronic diseases, medications, certain lifestyles including excessive intake of foods high in saturated or trans fats, physical inactivity, obesity and smoking also contribute to blood lipid disorders. To bring awareness about prevention, management, and treatment of blood lipid disorders, the Government is promoting a healthy diet and physical activity participation, early detection and management of blood lipid disorders as well as update and review of drug lists and clinical protocols regularly to ensure impartial access to drugs and therapies of proven safety and efficacy. The overall scenario is predicted to make healthy growth of the market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Lipid Disorder Treatment. The growth and trends of Lipid Disorder Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Lipid Disorder Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Atorvastatin
Fluvastatin
Rosuvastatin
Simvastatin
Pravastatin
Other Drugs

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Indication

Familial Combined Hyperlipidemia
Familial Defective Apolipoprotein B-100
Familial Dysbetalipoproteinemia
Familial Hypertriglyceridemia
Heterozygous Familial Hypercholesterolemia
Other Indications

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lipid Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lipid Disorder Treatment market include Pfizer Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., Emcure Pharmaceuticals Ltd., Teva Pharmaceuticals Industries Ltd., Mylan N.V., Kowa Pharmaceuticals America Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Wockhardt Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11212596

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIPID DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Atorvastatin Historic and Forecast Sales By Regions
5.5. Fluvastatin Historic and Forecast Sales By Regions
5.6. Rosuvastatin Historic and Forecast Sales By Regions
5.7. Simvastatin Historic and Forecast Sales By Regions
5.8. Pravastatin Historic and Forecast Sales By Regions
5.9. Other Drugs Historic and Forecast Sales By Regions

6. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data
6.3. Analysis By Distribution Channel
6.4. Retail Pharmacies Historic and Forecast Sales By Regions
6.5. Hospital Pharmacies Historic and Forecast Sales By Regions
6.6. Online Pharmacies Historic and Forecast Sales By Regions

7. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data
7.3. Analysis By Indication
7.4. Familial Combined Hyperlipidemia Historic and Forecast Sales By Regions
7.5. Familial Defective Apolipoprotein B-100 Historic and Forecast Sales By Regions
7.6. Familial Dysbetalipoproteinemia Historic and Forecast Sales By Regions
7.7. Familial Hypertriglyceridemia Historic and Forecast Sales By Regions
7.8. Heterozygous Familial Hypercholesterolemia Historic and Forecast Sales By Regions
7.9. Other Indications Historic and Forecast Sales By Regions

8. GLOBAL LIPID DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE LIPID DISORDER TREATMENT COMPANIES

9.1. Lipid Disorder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF LIPID DISORDER TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novartis AG
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. AstraZeneca
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Merck & Co. Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Emcure Pharmaceuticals Ltd.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Teva Pharmaceuticals Industries Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Mylan N.V.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Kowa Pharmaceuticals America Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Glenmark Pharmaceuticals Ltd.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Sun Pharmaceuticals Industries Ltd.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Wockhardt Limited
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies